Emergent BioSolutions’ rPA anthrax vaccine candidate is a purified recombinant protective antigen protein formulated with an alum adjuvant and is designed to induce antibodies that neutralise anthrax toxins.
As per the terms of the agreement, the base value is expected to fund activities related to process characterisation and assay validation, as well as formulation and stability studies.
Milestone-based options include completion of a Phase II clinical study and non-clinical efficacy studies, process validation, as well as consistency lot manufacture.
Emergent BioSolutions chairman and CEO Fuad El-Hibri said that the award solidifies Emergent’s anthrax franchise.